Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine patch titration in Japanese Alzheimer's patients
NCT01614886Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Primary completion
- May 2014
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation at 24 weeks. Started Jul 2012; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01614886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614886.